



(11) **EP 1 608 368 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
10.06.2009 Bulletin 2009/24

(45) Date of publication and mention
of the grant of the patent:
01.10.2008 Bulletin 2008/40

(21) Application number: **04720871.5**

(22) Date of filing: **16.03.2004**

(51) Int Cl.:
A61K 31/436^(2006.01) A61K 31/445^(2006.01)
A61P 37/00^(2006.01)

(86) International application number:
PCT/EP2004/002714

(87) International publication number:
WO 2004/082681 (30.09.2004 Gazette 2004/40)

(54) **PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF RAPAMYCIN OR ITS DERIVATIVE AND PIMECROLIMUS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)**

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT EINER KOMBINATION AUS RAPAMYCIN ODER SEINEN DERIVATEN UND PIMECROLIMUS ZUR BEHANDLUNG VON ENTZÜNDLICHER DARMERKRANKUNG (IBD)

COMPOSITIONS PHARMACEUTIQUES COMPRENANT UNE COMBINAISON DE RAPAMYCINE OU DE SON DERIVE ET DE PIMECROLIMUS POUR LE TRAITEMENT DE L' AFFECTION INTESTINALE INFLAMMATOIRE (IBD)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
LT LV

(30) Priority: **17.03.2003 GB 0306070**
25.03.2003 GB 0306868
15.08.2003 GB 0319226

(43) Date of publication of application:
28.12.2005 Bulletin 2005/52

(73) Proprietors:
• **NOVARTIS AG**
4056 Basel (CH)
Designated Contracting States:
BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
• **Novartis Pharma GmbH**
1230 Wien (AT)
Designated Contracting States:
AT

(72) Inventor: **MOORE, Henrietta**
A-2384 Breitenfurt (AT)

(56) References cited:
EP-A- 1 208 847 WO-A-99/24036
WO-A-02/089796 WO-A-03/057218
WO-A-03/094990 US-A- 6 004 973

- **MARSLAND ALEXANDER M ET AL: "The macrolide immunosuppressants in dermatology: mechanisms of action." [Online] November 2002 (2002-11), EUROPEAN JOURNAL OF DERMATOLOGY : EJD. 2002 NOV-DEC, VOL. 12, NR. 6, PAGE(S) 618 - 622 , XP002284186 ISSN: 1167-1122 John Libbey Eurotext Retrieved from the Internet: URL:http://www.john-libbey-eurotext.fr/en/revues/medecine/ejd/e-docs/00/01/87/58/art_icle.md?type=text.html [retrieved on 2004-06-07] page 2, paragraph 5**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 608 368 B8

- **BORNHÖVD E ET AL: "Macrolactam immunomodulators for topical treatment of inflammatory skin diseases." November 2001 (2001-11), JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. NOV 2001, VOL. 45, NR. 5, PAGE(S) 736 - 743 , XP002284187 ISSN: 0190-9622 the whole document**